Cancer Vaccines To Pay Off? Pivotal Candidates May Yield Two BLAs In 2006
This article was originally published in Pharmaceutical Approvals Monthly
FDA appears likely to review both personalized and "off-the-shelf" cancer vaccine BLAs in 2006, potentially rewarding the oncology community’s durable faith in active immunotherapy.
You may also be interested in...
Following the Phase III failure of its pancreatic cancer vaccine Panvac-VF, developer Therion is for sale. The company anticipates closing within several months, Therion said in a June 28 announcement. The firm no longer plans to file a BLA, which it had been targeting for filing by year-end (1Pharmaceutical Approvals Monthly May 2006, p. 11). A Phase III trial of Therion's prostate cancer vaccine Prostvac-VF remains on track to start later this year...
Dendreon plans to submit a BLA for its prostate cancer vaccine Provenge in 2006 following FDA feedback suggesting that existing data is sufficient for filing, the firm says.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011